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Introduction
Sudden unexpected death in epilepsy (SUDEP) primarily affects young adults. Among neurological conditions causing loss of potential years of life, SUDEP ranges second only to stroke [1] . SUDEP is the leading cause of death related directly to seizures [2, 3] .
A potential role of antiepileptic drugs (AEDs) in SUDEP has been discussed for several years, and, at present, the leading interpretation of the existing literature is that there is no scientific evidence that any AED can increase the risk [4] [5] [6] [7] [8] . The aim of this review is to identify and discuss the strong scientific reasons for giving greater nuance to this widespread perception.
Search strategy and selection criteria
We used PubMed to search for references, and references from relevant articles, using the search terms "epilepsy", "epileptic", "antiepileptic", "drugs", "seizures", "risk factors", "sudden", "death", "genetic", "mechanisms", "cardiac", "arrhythmia" and "psychiatric". Only articles in English and published between 1970 and June 2016 were included.
References were selected from the identified articles according to their relevance to this review. Using the combination of search the terms "SUDEP and epilepsy and risk factors" 233 articles were identified. Among these all studies using living patients with epilepsy as controls examining a possible connection between individual AEDs and SUDEP were selected and included in the review.
Pathophysiological mechanisms and risk factors SUDEP is defined as "sudden, unexpected, witnessed or unwitnessed, nontraumatic and nondrowning death, occurring in benign circumstances, in an individual with epilepsy, with or without evidence for a seizure and excluding documented status epilepticus (seizure duration ≥ 30 min or seizures without recovery in between), in which postmortem
examination does not reveal a cause of death" [9] . The majority of documented observed cases of SUDEP have occurred in association with a generalized tonic-clonic seizure (GTCS) [10] [11] [12] , although recent evidence suggests that it may also occur without an associated seizure [13] . The cause in individual cases is usually unknown. Nevertheless, there is considerable evidence that respiratory or cardiac mechanisms, separately or in combination, are often involved [14] . Based on documented cases of SUDEP, in which seizure activity was abruptly followed by flattening of the EEG, electrocerebral shutdown has also been proposed as a separate mechanism [15] . Interestingly, the occurrence of ictal hypoxia significantly increases the risk of concomitant cardiac dysfunction [16] . Interictally, at the group level, the occurrence of cardiac arrhythmias in individuals with epilepsy does not differ significantly from that in the general population [17, 18] . However, arrhythmias occur in a significant proportion of seizures, ranging from benign sinustachycardia or bradycardia [19] [20] [21] [22] [23] There appears to be broad agreement that if a significant difference is detected between the proportion of SUDEP victims on a certain AED and the proportion on the same drug among controls, then when evaluating whether there is a causal relationship the numbers should be corrected for the frequency of GTCSs [4, 5, 35] . Importantly, however, it has not been acknowledged that in correcting for seizure frequency, the influence of AED efficacy, which has been demonstrated to be crucial in the prevention of SUDEP, is simultaneously eliminated [34] . A relationship could be regarded as causal, in the sense that an increased occurrence of SUDEP may be caused by an unfavourable choice of AED that provides inferior protection against GTCSs.
Channelopathies and AEDs
Channelopathies are diseases caused by mutations in genes coding for ion channels. They are often genotypically and phenotypically heterogeneous, i.e., a certain genetic disorder may be caused by different mutations, and a given mutation may give rise to different phenotypes in the same family [36, 37] . The genetic epilepsies have been associated with mutations in genes coding for sodium-, potassium-, calcium-and chloride channels, as well as the nicotinergic acetylcholine receptor and the gamma-aminobutyric acid (GABA) receptor. Among these, sodium channel mutations are the most common [38, 39] .
Although non channel mechanisms may be involved, blockade of ion channels is the most important mechanism of action for the majority of AEDs [40] . Many of these are sodium channel blockers and, when used to treat genetic epilepsy, may not only provide inferior efficacy, but even cause seizure aggravation. For example, the sodium channel blockers phenytoin (PHT), carbamazepine (CBZ), and lamotrigine (LTG) [41] can cause paradoxical seizure aggravation, particularly in juvenile myoclonic epilepsy of myoclonic jerks [42] , and LTG can aggravate severe myoclonic epilepsy of infancy (SMEI; Dravet syndrome) [43] , which is caused by a mutation in the neuronal sodium channel gene SCN1A [44] .
Nevertheless, investigations of possible associations between AEDs and SUDEP have been performed only at the group level, without examining the genetic epilepsies separately [4, 12, 26, 27, [45] [46] [47] .
Congenital long QT syndrome (cLQTS) is caused by mutations in genes coding for cardiac ion channels, mainly potassium channels and, in a smaller proportion, sodium channels [48, 49] . It is associated with prolongation of the QT interval in the ECG and a propensity to syncope, torsade de pointes arrhythmia, and ventricular fibrillation [48, 50] . Several drugs, including antipsychotics, antihistamines, and antibiotics, can inhibit the cardiac potassium ion current IKr, and several IKr blocking drugs have been excluded or withdrawn from the market because of an unacceptably high occurrence of QT interval prolongation, syncope, and sudden death [51, 52] . Importantly, individuals with the cLQTS are particularly vulnerable and should generally avoid IKr-blocking drugs [53] .
In recent years, increasing evidence has emerged indicating that cardiac and neuronal channelopathies are overlapping. Many of the cardiac ion channel genes causing cLQTS are also expressed in the brain [54] . Animal studies [55, 56] , along with clinical studies [57, 58] and casuistic reports [59] [60] [61] [62] , suggest that cardiac channelopathies may also be associated with epilepsy. Evidence for the converse, however, that neuronal channelopathies can predispose a patient to cardiac arrhythmia, is sparse. Nevertheless, in casuistic reports of SUDEP in patients with generalized epilepsy with febrile seizures plus (GEFS+) and Dravet syndrome, there has been discussion regarding whether a genetic disposition to fatal cardiac arrhythmia could occur, as the gene product of SCN1A, NaV1.1, is expressed in the heart of mammals [63, 64] .
Although non channel or non cardiac mechanisms may possibly be involved explaining an association between an AED and SUDEP a key question is whether drugs with the potential to prolong the QT interval can increase the risk of a fatal seizure-related cardiac arrhythmia in genetically predisposed individuals. This possibility was recently addressed in an Australian study of 61 SUDEP victims, in which genetic analysis revealed mutations indicating a predisposition to cardiac arrhythmia in 13 of the deceased; 7 % (4/61) had mutations in LQTS genes and 15 % (9/61) had mutations in other cardiac arrhythmia genes [65] .
Individual AEDs and SUDEP
Several AEDs are associated with abnormalities in the cardiac conduction system and rhythmicity, mainly in predisposed individuals [66] [67] [68] . CBZ and intravenous PHT can give rise to sinus bradycardia, sinus arrest, and atrioventricular block [69] [70] [71] , whereas lacosamide has shown a tendency to induce atrioventricular block [72] . In addition, the QT interval can be increased by retigabine (Trobalt European Public Assessment Report, EPAR. Committee for Medicinal Products for Human Use (CHMP): www.ema.europa.eu/ema/) and CBZ and primidone can shorten it [67, 73] . PHT, phenobarbital (PB), and LTG have been shown to inhibit the IKr [74, 75] and a possible role in SUDEP has been suggested. However, among epidemiological studies focusing on a possible relationship between AEDs and SUDEP, only CBZ and LTG have been suggested as being implicated (table 1) [12, 46, 47, 76, 77] .
CBZ and SUDEP CBZ was first discussed as a possible risk factor for SUDEP in a study from the Cardiff Epilepsy Unit in 1998, in which 85 % of SUDEP victims that were on AED therapy at the time of death were treated with CBZ, compared with only 38 % of controls (p < 0·01) [47] .
Importantly, in this cohort as many as 10 of the 14 SUDEP victims had idiopathic generalized epilepsy (IGE) [78] , and 11/14 were on CBZ which, when used in the treatment of IGE, may cause seizure aggravation (table 1) [79] . Three years later, a Swedish case-control study identified high levels of CBZ as a risk factor for SUDEP [46] , although it was emphasised that there was uncertainty regarding whether confounding factors could be present. However, in contrast, two later reports found no association between CBZ and SUDEP [27, 45] .
Furthermore, a large study that included 216 SUDEP cases concluded after correcting for the frequency of GTCSs, that neither the use of CBZ nor any other AED could increase the risk of SUDEP [4] . No increase in SUDEP risk associated with CBZ in monotherapy was detected in the crude analysis (odds ratio 0.7; 95 % CI 0.3 -1.4), as opposed to CBZ in polytherapy (odds ratio 2.8; 95 % CI 1.5 -5.3) [4] . As there was no increase in risk with monotherapy in the crude analysis, correction for seizure frequency, which principally eliminates the influence of AED efficacy, cannot explain the finding of a lack of association between CBZ in monotherapy and SUDEP. Nevertheless, a sub-group analysis of individuals with IGE was not performed, and an increased risk with CBZ in IGE cannot be completely excluded based on this study.
LTG and SUDEP
Following a clinical observation of four consecutive cases of SUDEP in females with idiopathic epilepsy that had all been treated with LTG in monotherapy, the question was raised of whether there could be a connection between treatment with LTG in idiopathic epilepsy and SUDEP [80] . One possible explanation that was discussed was that inhibition of the cardiac IKr current by LTG [74] could cause fatal arrhythmia in genetically predisposed individuals. Additionally, the preponderance of females could reflect the up to threefold higher risk of drug-induced torsade de pointes arrhythmia in females [81, 82] . In line with this, four years later the International League Against Epilepsy (ILAE) Commission on Epidemiology; Subcommission on Mortality, concluded from their combined analysis of 289 SUDEP cases from four different case-control studies that, using univariate analysis, treatment with LTG was associated with a significantly increased risk of SUDEP [76] . Importantly, however, when "IGE" and "not IGE" were analysed separately, the elevated risk was only present in IGE. Conforming with this, a Norwegian study found that the proportion of female SUDEP victims on LTG was significantly higher than the proportion of living female controls with epilepsy on LTG, and that there was a fivefold higher incidence of SUDEP in females on LTG than in females with epilepsy that were not on LTG [77] . Again, there were no indications of an increased risk in symptomatic epilepsy; the increased risk associated with LTG treatment was apparently only present in idiopathic epilepsy. At the same time as the Norwegian report was published, a new report concluded that, after correcting for the frequency of GTCSs, neither the use of LTG nor any other AED causes an increased risk of SUDEP, as opposed to a high frequency of GTCSs [4] . As the correction for seizure frequency was performed only at the group level, the patient material with an increased risk (IGE) of SUDEP was diluted by the larger subgroup without an increased risk (not IGE). Consequently, the conclusion that there is no causal relationship between LTG treatment and SUDEP that is based on this analysis, is, in our opinion, not valid for the subgroup with IGE.
Interestingly, however, and supporting the results of the Norwegian study [77] , the odds ratio for SUDEP in patients on LTG in monotherapy compared with controls was 6.6 for females (95% CI 0.3-174.9) and 0.4 in males (95% CI 0.1-2.8) [4] . Again, the analysis was performed only at the group level, and therefore it is possible that the lack of statistical significance could be due to dilution of the material.
The importance of AED efficacy in protection against SUDEP was not acknowledged in the ILAE study that claimed an absence of causal relationship between LTG use and SUDEP [4] .
Clinical studies have indicated that LTG in IGE provides inferior seizure protection compared with valproate [83, 84] , which has been recommended as a first-line drug in IGE because of its efficacy [85] . As the most important risk factor for SUDEP is probably a high frequency of GTCSs, use of LTG in IGE with GTCSs could be expected to result in more SUDEP. In summary, the increased occurrence of SUDEP in patients with IGE on LTG could be partly due to a cardiac side effect in genetically predisposed individuals, and partly due to insufficient efficacy; both factors are of importance and may both contribute to SUDEP.
AEDs in psychiatry and neuropathic pain
AEDs are also widely used in the treatment of neuropathic pain and psychiatric disorders. To our knowledge, there is no evidence of an increased occurrence of sudden death associated with neuropathic pain syndromes, but among individuals with psychiatric diseases the incidence of sudden death is significantly elevated [86] . The reasons for this are probably multifactorial, including an increased occurrence of cardiovascular disease in this population [87] . However, several antipsychotics and antidepressants possess the ability to inhibit the IKr and have been associated with increased risk of QT interval prolongation, torsade de pointes arrhythmia, and sudden death [88] . Whether AEDs that can inhibit the IKr contribute to the greater occurrence of arrhythmias and sudden death in patients with psychiatric disorders has not been explored scientifically as far as we are aware. However, combining drugs with IKr blocking properties may be hazardous [74, 88] ; thus treatment with a combination of an IKrblocking AED and a psychotropic drug, particularly in patients with a predisposition to cardiac arrhythmia, may put the patients at an unacceptably elevated risk of sudden death.
Conclusions
A high frequency of GTCSs is probably the single most important risk factor for SUDEP, and therefore effective AED therapy remains a cornerstone in its prevention. Thus, optimal choice of treatment, according to epilepsy syndrome and seizure type, is key for reducing the risk of SUDEP.
Because the efficacy and safety profiles of AEDs may differ, studies on possible associations between AED treatment and SUDEP should be performed separately for genetic epilepsy and symptomatic or cryptogenic epilepsy.
In patients with a predisposition to cardiac arrhythmia, caution should be exercised when considering the introduction of AEDs with the potential to interfere with cardiac rhythmicity or conduction system. Caution is particularly recommended in prescribing LTG for treatment of females with IGE and GTCSs. Importantly, however, this should not discourage the use of LTG in symptomatic or cryptogenic epilepsy in which there is no scientific evidence suggesting an increased risk.
Advances in detecting mutations that may predispose patients to serious cardiac arrhythmias will hopefully enable clinicians to improve safety in the treatment of people with epilepsy. 
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